TG Therapeutics (TGTX) Reports Q4 Loss of $0.48/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
TG Therapeutics, Inc. Announces Fourth Quarter and Year-End 2016 Financial Results and Business Update
March 10, 2017 7:30 AM ESTCompany solidifies balance sheet with approximately $89M in gross proceeds through the combination of $57.5M public offering and $31M from at-the-market (ATM) sales facility completed prior to the offering
Investor conference call to be held today, Friday March 10, 2017 at 8:30am ET Â
NEW YORK, March 10, 2017 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced its financial results for the fourth quarter and year ended December 31, 2016 and provided recent company developments along with a business outlook for 2017.
The Company announced that through the combination of an underwritten... More
